Search

Displaying results 2201 - 2210 of 10000 in total
  1. Drug

    Erenumab

    go.drugbank.com/drugs/DB14039
    ApprovedInvestigational

    CGRP receptor, which is believed to play a critical role in migraine [L2823]. … In particular, erenumab-aooe is a human immunoglobulin G2 monoclonal antibody that has high affinity binding to the CGRP receptor [FDA Label].

    Products: Pasurta 70mg/ml Solution for Injection in a Prefilled Syringe, AIMOVIG SOLUTION FOR INJECTION IN PRE-FILLED PEN 70MG/ML
  2. Drug

    Ethoxzolamide

    go.drugbank.com/drugs/DB00311
    ApprovedWithdrawn

    Ethoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.

  3. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset … Cangrelor was approved by the FDA in June 2015 for intravenous application.

  4. Drug

    Doxylamine

    go.drugbank.com/drugs/DB00366
    ApprovedInvestigationalVet approved

    It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.

    Mixtures: N - Time, N - Time SinusSynonyms: N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine, Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether
  5. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). … [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]

  6. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. … Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone.

  7. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. … Liotrix is a synthetically derived thyroid hormone replacement preparation.

    Categories: l-Triiodothyronine
  8. Drug

    Lenograstim

    go.drugbank.com/drugs/DB13144
    ApprovedWithdrawn

    Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.

  9. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

    Mixtures: Ala Quin, PRECORT-A KREM
  10. Drug

    Eculizumab

    go.drugbank.com/drugs/DB01257
    ApprovedInvestigational

    [L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007. … [L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria